Literature DB >> 17905527

Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer.

Atsuya Takeda1, Etsuo Kunieda, Toshiaki Takeda, Michio Tanaka, Naoko Sanuki, Hirofumi Fujii, Naoyuki Shigematsu, Atsushi Kubo.   

Abstract

PURPOSE: To retrospectively analyze opacity changes near primary lung cancer tumors irradiated by using hypofractionated stereotactic radiotherapy (HSRT) to determine the presence or absence of tumor recurrence. METHODS AND MATERIALS: After review-board approval for a retrospective study, we examined data from 50 patients treated with curative intent for proven or highly suspected localized peripheral-lung cancer and followed up for at least 12 months. All patients had received 50 Gy in five fractions (80% isodose) and were followed up monthly with chest X-ray until clinical and X-ray findings stabilized. Follow-up computed tomography scans were performed 1 and 3 months after HSRT and thereafter at 3-month intervals during the first 2 years.
RESULTS: Median follow-up was 30.4 months (range, 12.0-73.8 months). Abnormal opacities that were suspicious for recurrent tumor appeared in 20 patients at a median of 20.7 months (range, 5.9-61.4 months). Only 3 patients were finally found to have recurrence; 14 were recurrence free but were suspected to have fibrosis, and findings for the other 3 patients were considered equivocal because of a short follow-up period (<or=6 months).
CONCLUSION: Radiation fibrosis, which may occur 1 year or longer after completion of HSRT, is difficult to distinguish from tumor recurrence. Even when opacities increase on follow-up radiologic scans, recurrence cannot be diagnosed conclusively based on image findings; biopsy occasionally is warranted.

Entities:  

Mesh:

Year:  2007        PMID: 17905527     DOI: 10.1016/j.ijrobp.2007.07.2383

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

Review 1.  New techniques for assessing response after hypofractionated radiotherapy for lung cancer.

Authors:  Sarah A Mattonen; Kitty Huang; Aaron D Ward; Suresh Senan; David A Palma
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

3.  Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung cancer, radiological suspicion of a local recurrence can be sufficient indication to proceed to salvage therapy.

Authors:  Timothy K Nguyen; David A Palma
Journal:  Transl Lung Cancer Res       Date:  2016-12

4.  Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Authors:  Feras Oskan; Yvonne Dzierma; Stefan Wagenpfeil; Christian Rübe; Jochen Fleckenstein
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 5.  Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?

Authors:  Sarah A Mattonen; Aaron D Ward; David A Palma
Journal:  Br J Radiol       Date:  2016-06-20       Impact factor: 3.039

Review 6.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 7.  The oligometastatic state - separating truth from wishful thinking.

Authors:  David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

8.  Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.

Authors:  Marguerite Tyran; Nathalie Charrier; Julien Darreon; Anne Madroszyk; Agnes Tallet; Naji Salem
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 9.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

10.  Can high-risk CT features suggest local recurrence after stereotactic body radiation therapy for lung cancer? A systematic review and meta-analysis.

Authors:  Tae-Hyung Kim; Sungmin Woo; Darragh F Halpenny; Yeon Joo Kim; Soon Ho Yoon; Chong Hyun Suh
Journal:  Eur J Radiol       Date:  2020-04-07       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.